4 syllables: I, ma, ti, nib. Stress on ma.
im-AT-in-ib
/ɪˈmætɪnɪb/
Imatinib is pronounced im-AT-in-ib (/ɪˈmætɪnɪb/). It has four syllables (I-ma-ti-nib), with the stress on "ma". Imatinib is a targeted cancer drug (a tyrosine kinase inhibitor) used to treat chronic myeloid leukemia and certain other cancers. The term names the chemical compound and its marketed presentations. In medical literature it appears as a proper noun and is pronounced with emphasis on the second syllable. Overall, it denotes a specific therapeutic agent rather than a common noun.
nounImatinib is a targeted cancer drug (a tyrosine kinase inhibitor) used to treat chronic myeloid leukemia and certain other cancers. The term names the chemical compound and its marketed presentations. In medical literature it appears as a proper noun and is pronounced with emphasis on the second syllable. Overall, it denotes a specific therapeutic agent rather than a common noun.
How to Pronounce Imatinib
"Imatinib was the first molecularly targeted therapy to demonstrate a dramatic response in chronic myeloid leukemia."
"Researchers published new data on imatinib's efficacy in treating gastrointestinal stromal tumors."
"The patient underwent lifelong monitoring while receiving imatinib as part of their cancer treatment."
Pronounce as /ɪˈmæ.tɪ.nɪb/ (US) or /ˌɪ.məˈtæ.nɪb/ (UK). Break it into four syllables: i-ma-ti-nib. The primary stress falls on the second syllable in many US and UK usages, with a secondary rhythm that keeps the 'ti' clearly separated rather than slurred. Start with a short, clipped ‘i’ then move to a strong ‘ma’ and finish with ‘ti-nib.’ You’ll hear it clearly in medical pronunciations and patient education materials.
Common errors include misplacing the stress (trying ‘i-MA-ti-nib’ or ‘i-ma-TI-nib’), merging the middle syllables into ‘imat-uh-nib,’ and dropping the final ‘b’ sound (imatin-). Correct by emphasizing the second syllable with a clear short ‘a’ in ‘ma,’ enunciating the ‘ti’ as a separate syllable, and finishing with a crisp ‘nib’ (n + ɪb). Practice aloud in four-note cadence: i-MA-ti-nib, keeping each vowel distinct.
In US English, the word tends to be /ɪˈmæ.tɪ.nɪb/ with strong second-syllable stress. UK speakers may place stress on the second or third syllable depending on phrasing, commonly /ˌɪ.məˈtæ.nɪb/. Australian pronunciation tends toward /ˌɪməˈtænɪb/, with vowel qualities closer to /æ/ in the second syllable and less rhoticity. All variants maintain four syllables; the key is keeping the ‘ti’ and ‘nib’ clearly separated and not slurring the consonants.
The difficulty comes from a multi-syllabic, four-syllable medical term with a stressed second syllable and a final ‘b’ that can be softly pronounced or devoiced depending on accent. The sequence ‘ti-nib’ invites a short consonant cluster transition; non-native speakers may blend syllables or misplace stress. Focusing on isolating each syllable and practicing with IPA helps: i - ma - ti - nib, with primary stress on the second syllable.
Unique issues include the presence of a ‘ti’ that often lands as a separate syllable and the final ‘b’ that tends to be devoiced in casual speech (so it may sound like ‘nɪp’ or ‘nɪb’ depending on speaker and pace). The root ‘-nib’ is a common pharmacological suffix, but the preceding ‘tɪ’ and the lead ‘ɪ’ on the first syllable require careful articulation to avoid conflating with similar drug names. IPA references aid precise articulation.
🗣️ Voice search tip: These questions are optimized for voice search. Try asking your voice assistant any of these questions about "Imatinib"!
Imatinib derives from the chemical name of its main structure, reflecting the imidazole-containing purine-like core and the tyrosine kinase inhibitory function. The name was coined by the pharmaceutical developers and later standardized in scientific literature and regulatory documents. Its early use arose in the context of designing targeted anticancer therapies in the 1990s, with the brand name Gleevec (US) or Glivec (EU). The root ‘-nib’ is a common suffix for kinase inhibitors, originating from biomedical nomenclature to indicate molecules that inhibit enzyme activity. The pronunciation settled quickly in medical communities, with emphasis typically on the second syllable. First known use in literature aligns with preclinical reports and early clinical trial publications around 2001–2002 as imatinib entered trials for CML and GIST.
💡 Etymology tip: Understanding word origins can help you remember pronunciation patterns and recognize related words in the same language family.
Help others use "Imatinib" correctly by contributing grammar tips, common mistakes, and context guidance.
💡 These words have similar meanings to "Imatinib" and can often be used interchangeably.
🔄 These words have opposite meanings to "Imatinib" and show contrast in usage.
📚 Vocabulary tip: Learning synonyms and antonyms helps you understand nuanced differences in meaning and improves your word choice in speaking and writing.
Words that rhyme with "Imatinib"
-bit sounds
Practice with these rhyming pairs to improve your pronunciation consistency:
🎵 Rhyme tip: Practicing with rhyming words helps you master similar sound patterns and improves your overall pronunciation accuracy.
